Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

[1]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[2]  H. Atkins,et al.  Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity , 2015, Nature Medicine.

[3]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[4]  V. Lowe,et al.  Remission of disseminated cancer after systemic oncolytic virotherapy. , 2014, Mayo Clinic proceedings.

[5]  A. Makrigiannis,et al.  Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  D. Mukhopadhyay,et al.  Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence , 2013, Nature Medicine.

[7]  H. Okada,et al.  GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. , 2013, Cancer research.

[8]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Bartlett,et al.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  R. Patt,et al.  Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. , 2013, Cancer research.

[11]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[12]  M. Caligiuri,et al.  NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors , 2012, Nature Medicine.

[13]  N. Lemoine,et al.  A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity , 2012, Clinical Cancer Research.

[14]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[15]  G. Cheng,et al.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[17]  K. Odunsi,et al.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.

[18]  R. Edwards,et al.  Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. , 2011, Blood.

[19]  D. Dingli,et al.  Pinhole Micro-SPECT/CT for Noninvasive Monitoring and Quantitation of Oncolytic Virus Dispersion and Percent Infection in Solid Tumors , 2011, Gene Therapy.

[20]  W. Fellows-Mayle,et al.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. , 2011, Cancer research.

[21]  Qian Zhang,et al.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy , 2009, BMC Genomics.

[22]  J. Talmadge,et al.  Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. , 2009, International immunopharmacology.

[23]  C. Nutt,et al.  Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide , 2009, Clinical Cancer Research.

[24]  J. Wolchok,et al.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit , 2008, Proceedings of the National Academy of Sciences.

[25]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[26]  D. Kirn,et al.  Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus , 2007, PLoS medicine.

[27]  D. Kirn,et al.  Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.

[28]  F. Marincola,et al.  Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. , 2007, Cancer research.

[29]  H. Atkins,et al.  Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Jiwon Kim,et al.  Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  B. Moss,et al.  Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. , 2005, Human gene therapy.

[32]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[33]  S. Libutti,et al.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.

[34]  R. Negrin,et al.  Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. , 2001, Blood.

[35]  L. Eisenlohr,et al.  Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma , 1999, Cancer Gene Therapy.

[36]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[37]  D. Kirn,et al.  First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  S. Nimmagadda,et al.  The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.

[39]  S. Thorne,et al.  Regulating cytokine function enhances safety and activity of genetic cancer therapies. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.